2014
DOI: 10.1038/bjc.2014.191
|View full text |Cite
|
Sign up to set email alerts
|

Phase I/II trial of definitive carbon ion radiotherapy for prostate cancer: evaluation of shortening of treatment period to 3 weeks

Abstract: Background:The purpose of this study was to evaluate the feasibility of a new shortened 3-week treatment schedule of carbon ion radiotherapy (CIRT) for prostate cancer.Methods:Beginning in May 2010, patients with T1b–T3bN0M0, histologically proven prostate adenocarcinoma were enrolled in the phase II trial of CIRT. Patients received 51.6 GyE in 12 fractions over 3 weeks (protocol 1002). The primary end point was defined as the incidence of late adverse events that were evaluated based on the Common Terminology… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

3
67
1

Year Published

2014
2014
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 53 publications
(71 citation statements)
references
References 43 publications
3
67
1
Order By: Relevance
“…Many of the reports originate from centers with much experience in particle therapy, mainly from Japan but are retrospective in nature and only very few cover a number of patients that will allow valid conclusions to be drawn [58, 59]. Prospective studies are usually of even smaller size [60]. Data on proton therapy are more robust, and proton therapy in standard fractionation is in routine use in many centers for definitive treatment of prostate cancer and detailed information is available [38, 61].…”
Section: Hypofractionated Radiotherapy With Protons and Ionsmentioning
confidence: 99%
“…Many of the reports originate from centers with much experience in particle therapy, mainly from Japan but are retrospective in nature and only very few cover a number of patients that will allow valid conclusions to be drawn [58, 59]. Prospective studies are usually of even smaller size [60]. Data on proton therapy are more robust, and proton therapy in standard fractionation is in routine use in many centers for definitive treatment of prostate cancer and detailed information is available [38, 61].…”
Section: Hypofractionated Radiotherapy With Protons and Ionsmentioning
confidence: 99%
“…Regarding the late grade 3 or greater morbidity, only one patient who was treated with 20 fractions suffered from GU complications, but no grade 4 or higher toxicity was observed . Recently, the results of a phase I/II prospective study to evaluate the feasibility of a more hypofractionated regimen using 51.6 GyE in 12 fractions for 3 weeks were reported from NIRS . A total of 46 patients (12 low‐risk, 9 intermediate‐risk and 25 high‐risk cases) were enrolled in that study.…”
Section: Clinical Results In Prostate Cancermentioning
confidence: 99%
“…Regarding acute toxicity, just two patients (4%) showed grade 2 urinary frequency, and no other acute grade 2 toxicities were observed. Regarding the late toxicities, no grade 2 or greater toxicities were observed in any patients within the median follow‐up period of 32 months . In addition, at the Ion Beam Therapy Center in Saga, Japan, a phase II prospective study using 51.6 GyE in 12 fractions for 3 weeks began in August 2013.…”
Section: Clinical Results In Prostate Cancermentioning
confidence: 99%
“…To overcome this issue for the future, hypofractionation is a promising strategy, especially for prostate cancer treatment, based on radiobiological models . In fact, several studies of hypofractionated particle beam RT for prostate cancer have been carried out, and reported the same or lower incidences of adverse events as those seen with conventional photon beam RT using standard fractionation . Further confirmation of the feasibility and efficacy of hypofractionated particle beam RT will enable an increase in patient volume and reduction in the cost per patient.…”
Section: Future Prospectsmentioning
confidence: 99%